BACKGROUND: Childhood acute lymphoblastic leukemia (ALL) with current cure rates reaching 80% emphasizes the necessity to determine treatment related long-term effects. The present study examines the prevalence of and the risk factors for overweight and obesity in a cohort of ALL survivors treated and living in the French speaking part of Switzerland. METHODS: In this retrospective two-center study, height and weight of 54 patients diagnosed with ALL in first complete remission and treated with chemotherapy only were recorded at specified time points during treatment and off-therapy. Body mass index (BMI) and its age- and gender-adjusted standard deviation score (BMI-SDS) were calculated for the patients and their parents separately. Overweight and obesity were defined by a threshold of BMI-SDS >1.645 and BMI-SDS >1.96, respectively. RESULTS: At last follow-up, 16 (30%) of the 54 survivors were overweight and 10 (18%) were obese. The off-treatment period was most at risk with 11 of the 16 becoming overweight and 9 of the 10 becoming obese during that period. Overweight/obesity at diagnosis and abnormal maternal BMI were significantly associated with abnormal weight at follow-up, while age at diagnosis, gender, cumulative dose of steroids and paternal BMI showed no association. CONCLUSIONS: Consistent with published evidence from other regions of the developed and developing world, there is a significant prevalence of obesity in young ALL survivors in the French speaking part of Switzerland. Factors significantly associated with this late effect were mostly related to the familial background rather than to the treatment components. (c) 2008 Wiley-Liss, Inc.
BACKGROUND: Childhood acute lymphoblastic leukemia (ALL) with current cure rates reaching 80% emphasizes the necessity to determine treatment related long-term effects. The present study examines the prevalence of and the risk factors for overweight and obesity in a cohort of ALL survivors treated and living in the French speaking part of Switzerland. METHODS: In this retrospective two-center study, height and weight of 54 patients diagnosed with ALL in first complete remission and treated with chemotherapy only were recorded at specified time points during treatment and off-therapy. Body mass index (BMI) and its age- and gender-adjusted standard deviation score (BMI-SDS) were calculated for the patients and their parents separately. Overweight and obesity were defined by a threshold of BMI-SDS >1.645 and BMI-SDS >1.96, respectively. RESULTS: At last follow-up, 16 (30%) of the 54 survivors were overweight and 10 (18%) were obese. The off-treatment period was most at risk with 11 of the 16 becoming overweight and 9 of the 10 becoming obese during that period. Overweight/obesity at diagnosis and abnormal maternal BMI were significantly associated with abnormal weight at follow-up, while age at diagnosis, gender, cumulative dose of steroids and paternal BMI showed no association. CONCLUSIONS: Consistent with published evidence from other regions of the developed and developing world, there is a significant prevalence of obesity in young ALL survivors in the French speaking part of Switzerland. Factors significantly associated with this late effect were mostly related to the familial background rather than to the treatment components. (c) 2008 Wiley-Liss, Inc.
Authors: Susan J Lindemulder; Linda C Stork; Bruce Bostrom; Xiaomin Lu; Meenakshi Devidas; Stephen Hunger; Joseph P Neglia; Nina S Kadan-Lottick Journal: Pediatr Blood Cancer Date: 2015-02-07 Impact factor: 3.167
Authors: Fang Fang Zhang; Michael J Kelly; Edward Saltzman; Aviva Must; Susan B Roberts; Susan K Parsons Journal: Pediatrics Date: 2014-02-17 Impact factor: 7.124
Authors: M Frank Erasmus; Ksenia Matlawska-Wasowska; Ichiko Kinjyo; Avanika Mahajan; Stuart S Winter; Li Xu; Michael Horowitz; Diane S Lidke; Bridget S Wilson Journal: Sci Signal Date: 2016-11-29 Impact factor: 8.192
Authors: Janice S Withycombe; Lynette M Smith; Jane L Meza; Carrie Merkle; Melissa Spezia Faulkner; Leslie Ritter; Nita L Seibel; Ki Moore Journal: Pediatr Blood Cancer Date: 2014-11-18 Impact factor: 3.167
Authors: Austin L Brown; Philip J Lupo; Heather E Danysh; Mehmet F Okcu; Michael E Scheurer; Kala Y Kamdar Journal: J Pediatr Hematol Oncol Date: 2016-08 Impact factor: 1.289
Authors: Adam J Esbenshade; Jill H Simmons; Tatsuki Koyama; Elizabeth Koehler; James A Whitlock; Debra L Friedman Journal: Pediatr Blood Cancer Date: 2011-03 Impact factor: 3.167
Authors: Frances A Tylavsky; Karen Smith; Harriet Surprise; Sarah Garland; Xiaowei Yan; Elizabeth McCammon; Melissa M Hudson; Ching-Hon Pui; Sue C Kaste Journal: Pediatr Blood Cancer Date: 2010-12-15 Impact factor: 3.167